- Home
- BDJ vs NEO Comparison
BDJ vs NEO Comparison
Compare BDJ & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDJ | NEO |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | BDJ | NEO |
|---|---|---|
| Price | $9.51 | $12.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 561.6K | ★ 2.0M |
| Earning Date | 01-01-0001 | 02-17-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,162,000.00 |
| Revenue This Year | N/A | $10.90 |
| Revenue Next Year | N/A | $9.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $6.91 | $4.72 |
| 52 Week High | $8.66 | $15.32 |
Technical Indicators
Market Signals| Indicator | BDJ | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 57.47 |
| Support Level | $9.47 | $12.31 |
| Resistance Level | $9.62 | $13.29 |
| Average True Range (ATR) | 0.09 | 0.64 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 68.49 | 60.00 |
Price Performance
Historical ComparisonAbout BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.